United Therapeutics Corp (UTHR) Price and Market Data

United Therapeutics Corp is a biotechnology company focused on developing treatments for pulmonary arterial hypertension (PAH), a rare and progressive condition characterized by elevated blood pressure in the arteries of the lungs. Its PAH portfolio is centered largely on the prostacyclin pathway, with several therapies based on the molecule treprostinil. In the United States, the company markets commercial PAH treatments including Tyvaso DPI (treprostinil) inhalation powder, Remodulin Injection, Orenitram (treprostinil) extended-release tablets, Adcirca (tadalafil) tablets, and Unituxin. Tyvaso DPI is its largest revenue-generating product. United Therapeutics operates in the United States and internationally, with the U.S. accounting for the majority of its revenue.